A Study of SHR-2173 in Participants With Primary IgA Nephropathy

This study is a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the efficacy and safety of SHR-2173 in patients with Primary IgA Nephropathy(IgAN). The study consists of a screening period, a run-in period, a 48-week double-blind treatment period, and a 12-week follow-up period. Approximately 84 IgAN patients will be included.

NCT Number	NCT07354932
Lead Sponsor	Guangdong Hengrui Pharmaceutical Co., Ltd
Conditions	Primary IgA Nephropathy
Enrollment	84 participants
Start Date	2026-03-09
Primary Completion	2027-04 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-13